Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PTPRC | P08575 | 1/20 | 0.30 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.30 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | PTPRB | P23467 | 1/20 | 0.30 |
| ▸ | PTPRE | P23469 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2305382 | 1.00 | KDM4E (0.35) | KDM4EPTPRCPTPN2PTPN1PTPRB | |
| SCHEMBL28671689 | 0.89 | KDM4E (0.40) | KDM4E | |
| SCHEMBL18988677 | 0.83 | — | — | |
| SCHEMBL17525371 | 0.74 | KMT2A (0.52) | KDM4E | |
| SCHEMBL7354510 | 0.72 | KDM4E (0.50) | KDM4E | |
| SCHEMBL7345401 | 0.72 | — | — | |
| SCHEMBL7351663 | 0.70 | KDM4E (0.53) | KDM4E | |
| SCHEMBL18989284 | 0.69 | ALDH1A1 (0.36) | KDM4E | |
| SCHEMBL18989201 | 0.69 | KDM4E (0.34) | KDM4E | |
| SCHEMBL56294 | 0.68 | ALDH1A1 (0.36) | KDM4EPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120316150-A1 | AMIDE COMPOUNDS USEFUL IN THERAPY | PFIZER INC. | 2012-12-13 | — | — | US | disclosed |
| US-8232269-B2 | Amide compounds useful in therapy | PFIZER INC. (US) | 2012-07-31 | — | — | US | disclosed |
| EP-2350017-A1 | AMIDE COMPOUNDS USEFUL IN THERAPY | Pfizer Limited (GB) | 2011-08-03 | — | — | EP | disclosed |
| US-20100249091-A1 | Amide Compounds Useful in Therapy | GIBSON KARL RICHARD | 2010-09-30 | — | — | US | disclosed |
| WO-2010032200-A1 | AMIDE COMPOUNDS USEFUL IN THERAPY | PFIZER LIMITED (GB) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249091-A1 | Amide Compounds Useful in Therapy | PTGER3, PTGER1, PTGER2 | KDM4E 2261/4885PTPRC 4790/4885PTPN2 4683/4885 |
| US-20120316150-A1 | AMIDE COMPOUNDS USEFUL IN THERAPY | GNRHR, RXFP1, ARG1 | KDM4E 642/4885PTPRC 4872/4885PTPN2 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.